From Financial Modeling Prep: 2025-05-15 20:00:00

Rhythm Pharmaceuticals has a ROIC of -62.80% and a WACC of 15.89%, indicating it is not generating returns above its cost of capital. Deciphera Pharmaceuticals, Inc. (DCPH) shows a slightly more favorable cost structure than Rhythm Pharmaceuticals, though both operate at a loss. Krystal Biotech, Inc. (KRYS) is an outlier with a positive ROIC, suggesting efficient capital utilization within the biopharmaceutical industry. AnaptysBio, Inc. (ANAB) has a ROIC of -26.40% and a WACC of 13.46%, with a less negative ratio than other companies operating at a loss.



Read more at Financial Modeling Prep:: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Financi…